Zeria Pharmaceutical Co., Ltd.
【Zeria Pharmaceutical】Financial Results for 2026 | Sales of ¥89.1 billion, Net Profit of ¥8.4 billion increase
Zeria Pharmaceutical's fiscal year ending March 2026 recorded sales of ¥89.1 billion (YoY +2.1%), net profit of ¥8.4 billion (down 14.9% YoY), with an increased overseas sales ratio of 59.3%. The company expects revenue and profit growth this term, with dividends also planned to be increased.
Key Figures
- Sales: ¥89,159 million (YoY +2.1%)
- Net profit attributable to owners of parent: ¥8,454 million (−14.9%)
- Dividend: ¥49 (planned increase)
AI要約
Performance Overview
The consolidated financial results for the fiscal year ending March 2026 show sales of ¥89.1 billion (YoY +2.1%), operating income of ¥12.4 billion (+1.4%), and net profit of ¥8.4 billion (−14.9%). The overseas sales ratio expanded to 59.3%, demonstrating solid growth in both the medical pharmaceuticals and consumer health care businesses. The medical pharmaceuticals segment performed well with ulcerative colitis and infectious disease treatments, while the consumer segment continued strong with the Heparize series. R&D expenses decreased to ¥3.7 billion.
Outlook and Shareholder Impact
For the fiscal year ending March 2027, projections indicate sales of ¥95.0 billion (+6.6%) and net profit of ¥10.0 billion (+18.3%), aiming for revenue and profit growth. The dividend is planned to increase by ¥2 to ¥49 per share, reflecting a focus on shareholder returns. The company will promote overseas expansion and new drug development to achieve long-term growth.
Zeria Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
